0000950170-24-015963.txt : 20240215
0000950170-24-015963.hdr.sgml : 20240215
20240215164526
ACCESSION NUMBER: 0000950170-24-015963
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240213
FILED AS OF DATE: 20240215
DATE AS OF CHANGE: 20240215
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Brown Jason Parker
CENTRAL INDEX KEY: 0001993170
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38958
FILM NUMBER: 24644477
MAIL ADDRESS:
STREET 1: KARUNA THERAPEUTICS, INC.
STREET 2: 99 HIGH STREET, 26TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02110
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Karuna Therapeutics, Inc.
CENTRAL INDEX KEY: 0001771917
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 270605902
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 99 HIGH STREET
STREET 2: 26TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02110
BUSINESS PHONE: 857-449-2244
MAIL ADDRESS:
STREET 1: 99 HIGH STREET
STREET 2: 26TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02110
4
1
ownership.xml
4
X0508
4
2024-02-13
false
0001771917
Karuna Therapeutics, Inc.
KRTX
0001993170
Brown Jason Parker
C/O KARUNA THERAPEUTICS, INC.
99 HIGH STREET, 26TH FLOOR
BOSTON
MA
02110
false
true
false
false
Chief Financial Officer
false
Common Stock
2024-02-13
4
F
false
278
318
D
21167
D
Restricted Stock Units
2024-02-13
4
A
false
10306
0
A
Common Stock
10306
10306
D
Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the partial vesting of restricted stock units ("RSUs") previously granted to the Reporting Person on February 13, 2023.
Reflects the annual equity award to the reporting person under the Karuna Therapeutics, Inc. 2019 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock, provided that, at the effective time of the proposed merger transaction among the Issuer, Bristol-Myers Squibb Company and Miramar Merger Sub Inc., this RSU award will convert into a cash award equal to the product of (i) the total number of shares of the Issuer's common stock subject to this RSU award immediately prior to such effective time, and (ii) $330. The RSUs or, after such conversion, the cash award, shall vest annually in four equal installments on each of February 13, 2025, February 13, 2026, February 13, 2027 and February 13, 2028, subject to the reporting person's continued service through each such vesting date.
/s/ Mia Kelley, Attorney-in-Fact
2024-02-15